Overview

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Status:
Not yet recruiting

Trial end date:
2024-03-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP) therapy in GPI-1 and those who are and plan to stay on PAP therapy in GPI-2.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tirzepatide